Table Info

Table 2.

The alcohol amounts of fatty liver terms (NAFLD, MAFLD, SLD)

Alcohol amount	NAFLD	MAFLD	SLD
< 30 g/day for men; < 20 g/day for women	NAFLD	Dual etiology of fatty liver disease	MASLD
30–60 g/day for men; 20–50 g/day for women	AFLD	Dual etiology of fatty liver disease	MetALD
> 60 g/day for men; > 50 g/day for women	AFLD	Dual etiology of fatty liver disease	ALD

ALD: alcoholic liver disease; MAFLD: metabolic-associated fatty liver disease; MASLD: metabolic dysfunction-associated steatotic liver disease; MetALD: metabolic dysfunction and alcohol-related liver disease; NAFLD: non-alcoholic fatty liver disease

Declarations

Author contributions

MO: Writing—review & editing. AT: Writing—review & editing, Supervision. MEK: Conceptualization, Investigation. All authors read and approved the submitted version.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

Not applicable.

Copyright

Publisher’s note

Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.

References

Seitz HK, Moreira B, Neuman MG. Pathogenesis of Alcoholic Fatty Liver a Narrative Review. Life (Basel). 2023;13:1662. [DOI] [PubMed] [PMC]

Subramaniyan V, Chakravarthi S, Jegasothy R, Seng WY, Fuloria NK, Fuloria S, et al. Alcohol-associated liver disease: A review on its pathophysiology, diagnosis and drug therapy. Toxicol Rep. 2021;8:376–85. [DOI] [PubMed] [PMC]

Osna NA, Rasineni K, Ganesan M, Donohue TM Jr, Kharbanda KK. Pathogenesis of Alcohol-Associated Liver Disease. J Clin Exp Hepatol. 2022;12:1492–513. [DOI] [PubMed] [PMC]

Meroni M, Longo M, Rametta R, Dongiovanni P. Genetic and Epigenetic Modifiers of Alcoholic Liver Disease. Int J Mol Sci. 2018;19:3857. [DOI] [PubMed] [PMC]

Seitz HK, Stickel F. Risk factors and mechanisms of hepatocarcinogenesis with special emphasis on alcohol and oxidative stress. Biol Chem. 2006;387:349–60. [DOI] [PubMed]

Kong LZ, Chandimali N, Han YH, Lee DH, Kim JS, Kim SU, et al. Pathogenesis, Early Diagnosis, and Therapeutic Management of Alcoholic Liver Disease. Int J Mol Sci. 2019;20:2712. [DOI] [PubMed] [PMC]

Liu SY, Tsai IT, Hsu YC. Alcohol-Related Liver Disease: Basic Mechanisms and Clinical Perspectives. Int J Mol Sci. 2021;22:5170. [DOI] [PubMed] [PMC]

Zhong Z, Ramshesh VK, Rehman H, Liu Q, Theruvath TP, Krishnasamy Y, et al. Acute ethanol causes hepatic mitochondrial depolarization in mice: role of ethanol metabolism. PLoS One. 2014;9:e91308. [DOI] [PubMed] [PMC]

Grimaudo S, Pipitone RM, Pennisi G, Celsa C, Cammà C, Di Marco V, et al. Association Between PNPLA₃ rs738409 C>G Variant and Liver-Related Outcomes in Patients With Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol. 2020;18:935–44.e3. [DOI] [PubMed]

10.

Alharthi J, Bayoumi A, Thabet K, Pan Z, Gloss BS, Latchoumanin O, et al. A metabolic associated fatty liver disease risk variant in MBOAT7 regulates toll like receptor induced outcomes. Nat Commun. 2022;13:7430. [DOI] [PubMed] [PMC]

11.

Albillos A, de Gottardi A, Rescigno M. The gut-liver axis in liver disease: Pathophysiological basis for therapy. J Hepatol. 2020;72:558–77. [DOI] [PubMed]

12.

Vijay-Kumar M, Aitken JD, Carvalho FA, Cullender TC, Mwangi S, Srinivasan S, et al. Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. Science. 2010;328:228–31. [DOI] [PubMed] [PMC]

13.

Del Chierico F, Nobili V, Vernocchi P, Russo A, De Stefanis C, Gnani D, et al. Gut microbiota profiling of pediatric nonalcoholic fatty liver disease and obese patients unveiled by an integrated meta-omics-based approach. Hepatology. 2017;65:451–64. [DOI] [PubMed]

14.

Yuan J, Chen C, Cui J, Lu J, Yan C, Wei X, et al. Fatty Liver Disease Caused by High-Alcohol-Producing Klebsiella pneumoniae. Cell Metab. 2019;30:675–88.e7. [DOI] [PubMed]

15.

Li NN, Li W, Feng JX, Zhang WW, Zhang R, Du SH, et al. High alcohol-producing Klebsiella pneumoniae causes fatty liver disease through 2,3-butanediol fermentation pathway in vivo. Gut Microbes. 2021;13:1979883. [DOI] [PubMed] [PMC]

16.

Chen X, Zhang Z, Li H, Zhao J, Wei X, Lin W, et al. Endogenous ethanol produced by intestinal bacteria induces mitochondrial dysfunction in non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2020;35:2009–19. [DOI] [PubMed]

17.

Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77:1335–47. [DOI] [PubMed] [PMC]

18.

Xu HQ, Wang CG, Zhou Q, Gao YH. Effects of alcohol consumption on viral hepatitis B and C. World J Clin Cases. 2021;9:10052–63. [DOI] [PubMed] [PMC]

19.

Roerecke M, Vafaei A, Hasan OSM, Chrystoja BR, Cruz M, Lee R, et al. Alcohol Consumption and Risk of Liver Cirrhosis: A Systematic Review and Meta-Analysis. Am J Gastroenterol. 2019;114:1574–86. [DOI] [PubMed] [PMC]

20.

Kulkarni AV, Sarin SK. The bidirectional impacts of alcohol consumption and MAFLD for progressive fatty liver disease. Ther Adv Endocrinol Metab. 2023;14:20420188231178370. [DOI] [PubMed] [PMC]

21.

Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020;73:202–9. [DOI] [PubMed]

22.

Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78:1966–86. [DOI] [PubMed] [PMC]

23.

Kalinowski A, Humphreys K. Governmental standard drink definitions and low-risk alcohol consumption guidelines in 37 countries. Addiction. 2016;111:1293–8. [DOI] [PubMed]

24.

New Technology Boosts Clinical Study Design for Alcohol Medications Team [Internet]. [cited 2024 Oct 10]. Available from: https://www.niaaa.nih.gov/news-events/news-noteworthy/new-technology-boosts-clinical-study-design-alcohol-medications-team

25.

Jophlin LL, Singal AK, Bataller R, Wong RJ, Sauer BG, Terrault NA, et al. ACG Clinical Guideline: Alcohol-Associated Liver Disease. Am J Gastroenterol. 2024;119:30–54. [DOI] [PubMed] [PMC]

26.

Åberg F, Helenius-Hietala J, Puukka P, Jula A. Binge drinking and the risk of liver events: A population-based cohort study. Liver Int. 2017;37:1373–81. [DOI] [PubMed]

27.

Surial B, Bertholet N, Daeppen JB, Darling KEA, Calmy A, Günthard HF, et al. The Impact of Binge Drinking on Mortality and Liver Disease in the Swiss HIV Cohort Study. J Clin Med. 2021;10:295. [DOI] [PubMed] [PMC]

28.

Rumbolt C, Minuk GY. The effects of binge drinking on healthy and diseased livers. Can Liver J. 2021;4:93–8. [DOI] [PubMed] [PMC]

29.

Kerr WC, Fillmore KM, Marvy P. Beverage-specific alcohol consumption and cirrhosis mortality in a group of English-speaking beer-drinking countries. Addiction. 2000;95:339–46. [DOI] [PubMed]

30.

Simpson RF, Hermon C, Liu B, Green J, Reeves GK, Beral V, et al. Alcohol drinking patterns and liver cirrhosis risk: analysis of the prospective UK Million Women Study. Lancet Public Health. 2019;4:e41–8. [DOI] [PubMed] [PMC]

31.

Sharma P, Arora A. Clinical presentation of alcoholic liver disease and non-alcoholic fatty liver disease: spectrum and diagnosis. Transl Gastroenterol Hepatol. 2020;5:19. [DOI] [PubMed] [PMC]

32.

Staufer K, Huber-Schönauer U, Strebinger G, Pimingstorfer P, Suesse S, Scherzer TM, et al. Ethyl glucuronide in hair detects a high rate of harmful alcohol consumption in presumed non-alcoholic fatty liver disease. J Hepatol. 2022;77:918–30. [DOI] [PubMed]

33.

Zhu Y, Xu X, Fan Z, Ma X, Rui F, Ni W, et al. Different minimal alcohol consumption in male and female individuals with metabolic dysfunction-associated fatty liver disease. Liver Int. 2024;44:865–75. [DOI] [PubMed]

34.

Israelsen M, Torp N, Johansen S, Hansen CD, Hansen ED, Thorhauge K, et al. Validation of the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake: an analysis of data from a prospective cohort study. Lancet Gastroenterol Hepatol. 2024;9:218–28. [DOI] [PubMed]

35.

Ajmera VH, Terrault NA, Harrison SA. Is moderate alcohol use in nonalcoholic fatty liver disease good or bad? A critical review. Hepatology. 2017;65:2090–9. [DOI] [PubMed] [PMC]

36.

Hagström H, Hegmar H, Moreno C. Interactions between the metabolic syndrome and alcohol consumption increases the risk of liver disease. United European Gastroenterol J. 2024;12:168–76. [DOI] [PubMed] [PMC]

37.

Åberg F, Helenius-Hietala J, Puukka P, Färkkilä M, Jula A. Interaction between alcohol consumption and metabolic syndrome in predicting severe liver disease in the general population. Hepatology. 2018;67:2141–9. [DOI] [PubMed]

38.

Crabb DW, Im GY, Szabo G, Mellinger JL, Lucey MR. Diagnosis and Treatment of Alcohol-Associated Liver Diseases: 2019 Practice Guidance From the American Association for the Study of Liver Diseases. Hepatology. 2020;71:306–33. [DOI] [PubMed]

39.

Addolorato G, Abenavoli L, Dallio M, Federico A, Germani G, Gitto S, et al. Alcohol associated liver disease 2020: A clinical practice guideline by the Italian Association for the Study of the Liver (AISF). Dig Liver Dis. 2020;52:374–91. [DOI] [PubMed]

40.

Alcohol use: brief intervention for people with a long-term condition [Internet]. NICE; c2024 [cited 2024 Oct 10]. Available from: https://www.nice.org.uk/indicators/ind202-alcohol-use-brief-intervention-for-people-with-a-long-term-condition/IND202-20240507.pdf

41.

Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017;11:317–70. [DOI] [PubMed] [PMC]

42.

European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81:492–542. [DOI] [PubMed]

43.

Sinn DH, Kang D, Guallar E, Hong YS, Cho J, Gwak GY. Modest alcohol intake and mortality in individuals with elevated alanine aminotransferase levels: a nationwide cohort study. BMC Med. 2022;20:18. [DOI] [PubMed] [PMC]

44.

Mitchell T, Jeffrey GP, de Boer B, MacQuillan G, Garas G, Ching H, et al. Type and Pattern of Alcohol Consumption is Associated With Liver Fibrosis in Patients With Non-alcoholic Fatty Liver Disease. Am J Gastroenterol. 2018;113:1484–93. [DOI] [PubMed]

45.

Ferri S, Stefanini B, Mulazzani L, Alvisi M, Tovoli F, Leoni S, et al. Very Low Alcohol Consumption Is Associated with Lower Prevalence of Cirrhosis and Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease. Nutrients. 2022;14:2493. [DOI] [PubMed] [PMC]

46.

Llamosas-Falcón L, Probst C, Buckley C, Jiang H, Lasserre AM, Puka K, et al. How does alcohol use impact morbidity and mortality of liver cirrhosis? A systematic review and dose–response meta-analysis. Hepatol Int. 2024;18:216–24. [DOI] [PubMed]

47.

Åberg F, Puukka P, Salomaa V, Männistö S, Lundqvist A, Valsta L, et al. Risks of Light and Moderate Alcohol Use in Fatty Liver Disease: Follow-Up of Population Cohorts. Hepatology. 2020;71:835–48. [DOI] [PubMed]